This study is exploring a new approach for people with severe lung diseases like Idiopathic Pulmonary Fibrosis (IPF), emphysema, or COPD, who also have bone marrow failure. It tests whether having a lung transplant first, followed by a bone marrow transplant, can help restore both lung and blood cell function. The study uses specific treatments like Rituximab, Alemtuzumab, Fludarabine, and Thiotepa for conditioning, and then gives specially prepared hematopoietic stem cells (blood-forming cells). Researchers are looking at safety, including death, transplant failure, and other medical problems, for up to two years after the stem cell transplant. You might be able to join if you are between 18 and 60 years old and meet criteria for a lung transplant due to end-stage lung disease. The study is currently unclear on its recruitment status and plans to enroll 8 participants.

Study design

This is an interventional study with no specified phase, designed to enroll 8 participants. It does not mention randomization or blinding.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for up to 2 years after the stem cell transplant to monitor for death, engraftment failure, and non-hematologic events.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.